Literature DB >> 9891976

Dopamine D2 receptor dimers in human and rat brain.

P Zawarynski1, T Tallerico, P Seeman, S P Lee, B F O'Dowd, S R George.   

Abstract

In order to determine whether dimers of dopamine D2 receptors can occur in mammalian brain, rat and human brain striatal membranes were photolabelled with two radioactive photoaffinity compounds selective for dopamine D2 receptors, [125I]azidophenethylspiperone and [125I]-4-azido-5-iodonemonapride. It was found that [125I]azidophenethylspiperone only labelled the D2 monomer, while [125I]-4-azido-5-iodonemonapride labelled both D2 monomers and dimers, despite the fact that very high concentrations (6 nM) of both radiocompounds were used. In addition, human cloned D2 receptors were probed with a D2-specific antibody, revealing multiple bands indicating the existence of trimers, tetramers and pentamers of D2 receptors. The different D2-binding patterns of the spiperone and benzamide congeners may explain the different densities of dopamine D2 receptors found with these two radioligands in human brain positron tomography in health and disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9891976     DOI: 10.1016/s0014-5793(98)01588-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A.

Authors:  R Lin; K Karpa; N Kabbani; P Goldman-Rakic; R Levenson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  Decreased number of striatal cholinergic interneurons and motor deficits in dopamine receptor 2-expressing-cell-specific Dyt1 conditional knockout mice.

Authors:  Fumiaki Yokoi; Janneth Oleas; Hong Xing; Yuning Liu; Kelly M Dexter; Carly Misztal; Melinda Gerard; Iakov Efimenko; Patrick Lynch; Matthew Villanueva; Raul Alsina; Shiv Krishnaswamy; David E Vaillancourt; Yuqing Li
Journal:  Neurobiol Dis       Date:  2019-10-13       Impact factor: 5.996

4.  Posttraumatic Brain Injury Cognitive Performance Is Moderated by Variation Within ANKK1 and DRD2 Genes.

Authors:  Michelle D Failla; John M Myrga; Joseph H Ricker; C Edward Dixon; Yvette P Conley; Amy K Wagner
Journal:  J Head Trauma Rehabil       Date:  2015 Nov-Dec       Impact factor: 2.710

5.  PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor.

Authors:  Andrew V Dix; Jennie L Conroy; Kara M George Rosenker; David R Sibley; Daniel H Appella
Journal:  ACS Med Chem Lett       Date:  2015-03-13       Impact factor: 4.345

Review 6.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

7.  Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.

Authors:  Sanjib Gogoi; Swati Biswas; Gyan Modi; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Med Chem Lett       Date:  2012-10-26       Impact factor: 4.345

Review 8.  Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism.

Authors:  Nathalie Ginovart
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

9.  Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization.

Authors:  Min Wang; Lin Pei; Paul J Fletcher; Shitij Kapur; Philip Seeman; Fang Liu
Journal:  Mol Brain       Date:  2010-09-02       Impact factor: 4.041

10.  Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression.

Authors:  Leisa A Glantz; John H Gilmore; David H Overstreet; Kayvon Salimi; Jeffrey A Lieberman; L Fredrik Jarskog
Journal:  Schizophr Res       Date:  2010-01-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.